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With the development of synthetic biology, substantial progress has been made in the low-cost production of 
plant natural products in microbes. Ginsenoside Rh2 is a potential anticancer drug isolated from medicinal plant 
ginseng. Fermentative production of ginsenoside Rh2 in yeast has recently been investigated as an alternative 
strategy compared to extraction from plants. However, the titer was quite low due to low catalytic capability of 
the key ginseng glycosyltransferase in microorganisms. Herein, we have demonstrated high-level production of 
ginsenoside Rh2 in Saccharomyces cerevisiae via repurposing an inherently promiscuous glycosyltransferase, 
UGT51 (Fig. 1). The semi-rationally designed UGT51 presented a ~1800-fold enhanced catalytic efficiency 
(kcat/Km) for converting protopanaxadiol to ginsenoside Rh2 in vitro. Introducing the mutant glycosyltransferase 
gene into yeast increased Rh2 production from 0.0032 to 0.39 mg/g dry cell weight (DCW). Further metabolic 
engineering, including preventing Rh2 degradation and increasing UDP-glucose precursor supply, increased 
Rh2 production to 2.90 mg/g DCW, which was more than 900-fold higher than the starting strain. Finally, fed-
batch fermentation in a 5-L bioreactor led to production of ~300 mg/L Rh2, which was the highest titer 
reported.In the present study, high production of ginsenoside Rh2 represented an excellent example of tailored 







Fig. 1. Evolution of glycosyltransferase UGT51 towards an efficient Rh2-synthase (A-B) and biosynthetic 
pathway of ginsenoside Rh2 in the engineered yeasts (C). 
 
